These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33249378)

  • 21. Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria.
    Walter E; Berger T; Bajer-Kornek B; Deisenhammer F
    J Med Econ; 2019 Mar; 22(3):226-237. PubMed ID: 30522373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Graves' disease induced by Alemtuzumab in relapsing-remitting multiple sclerosis patients: an observational study in a reference center.
    Rodríguez de Vera Gómez P; García-González JJ; Ravé-García R; López Ruiz R; Torres-Cuadro A; Eichau-Madueño S; García-García C; Martín-Hernández T
    J Endocrinol Invest; 2022 Oct; 45(10):1977-1990. PubMed ID: 35718853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recurrent intracerebral hemorrhage due to alemtuzumab treatment in a patient with multiple sclerosis: case report.
    İnci M; Gündüz T; Kürtüncü M; Eraksoy M
    Acta Neurol Belg; 2022 Oct; 122(5):1389-1391. PubMed ID: 35471765
    [No Abstract]   [Full Text] [Related]  

  • 24. Pulmonary embolism during the third cycle of alemtuzumab in a patient with relapsing multiple sclerosis.
    Habek M; Ruška B; Pavičić T; Alduk AM; Gabelić T; Adamec I
    Mult Scler Relat Disord; 2019 Oct; 35():5-6. PubMed ID: 31276912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis.
    Iovino A; Aruta F; Carotenuto A; Manganelli F; Iodice R
    Mult Scler Relat Disord; 2019 Feb; 28():98-100. PubMed ID: 30580038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.
    Berger T; Elovaara I; Fredrikson S; McGuigan C; Moiola L; Myhr KM; Oreja-Guevara C; Stoliarov I; Zettl UK
    CNS Drugs; 2017 Jan; 31(1):33-50. PubMed ID: 27882532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pneumonitis secondary to alemtuzumab in a patient with multiple sclerosis - A non-infectious cause of breathlessness.
    Whiteside D; Barth S; Datta A; Trip SA
    Mult Scler Relat Disord; 2018 May; 22():139-140. PubMed ID: 29684788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lambert-Eaton myasthenic syndrome associated with alemtuzumab administration.
    Hoffman BM; Zeid NA; Alam U; Caress JB
    Mult Scler Relat Disord; 2019 Jan; 27():131-132. PubMed ID: 30384197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alemtuzumab in multiple sclerosis: A retrospective analysis of occult hemorrhagic magnetic resonance imaging lesions and risk factors.
    Bachmann H; Cambron M; Casselman JW; Van Driessche V; Van Haute E; Van Hijfte L; Kelderman T; Hemelsoet D; Laureys G
    Eur J Neurol; 2021 Dec; 28(12):4209-4213. PubMed ID: 34374173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years.
    Oh J; Achiron A; Celius EG; Chambers C; Derwenskus J; Devonshire V; Hellwig K; Hutton GJ; McCombe P; Moore M; Rog D; Schneider JR; Simm RF; Sousa L; Vincent SG; Chung L; Daizadeh N; Mitchell C; Compston DAS;
    Mult Scler Relat Disord; 2020 Aug; 43():102146. PubMed ID: 32498033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autoimmune storm following alemtuzumab.
    Chan C; Beauchemin P; Sayao AL; Carruthers M
    BMJ Case Rep; 2022 Jun; 15(6):. PubMed ID: 35760506
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A real-world cohort analysis of alemtuzumab outcomes in relapsing multiple sclerosis.
    Herman JA; Khalighinejad F; York K; Radu I; Berrios Morales I; Ionete C; Hemond CC
    Mult Scler Relat Disord; 2021 Jan; 47():102619. PubMed ID: 33189019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.
    Meunier B; Rico A; Seguier J; Boutiere C; Ebbo M; Harle JR; Schleinitz N; Pelletier J
    Mult Scler; 2018 May; 24(6):811-813. PubMed ID: 29359614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
    Vermersch P; Martinelli V; Pfleger C; Rieckmann P; Alonso-Magdalena L; Galazka A; Dangond F; Phillips L
    Clin Ther; 2019 Feb; 41(2):249-260.e18. PubMed ID: 30846120
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute cardiotoxicity associated with alemtuzumab infusion for multiple sclerosis.
    Ahrabian D; Neill L; Bell R; Leary SM
    Mult Scler; 2020 May; 26(6):735-737. PubMed ID: 32298216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility.
    Montgomery SM; Kusel J; Nicholas R; Adlard N
    J Med Econ; 2017 Sep; 20(9):962-973. PubMed ID: 28635362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria during alemtuzumab treatment for multiple sclerosis.
    di Ioia M; Farina D; di Tommaso V; Travaglini D; Pietrolongo E; Onofrj M; de Luca G
    Mult Scler; 2018 May; 24(6):813-815. PubMed ID: 29359617
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful implementation of an automated electronic support system for patient safety monitoring: The alemtuzumab in multiple sclerosis safety systems (AMS3) study.
    Reddel SW; Barnett MH; Riminton S; Dugal T; Buzzard K; Wang CT; Fitzgerald F; Beadnall HN; Erickson D; Gahan D; Wang D; Ackland T; Thompson R
    Mult Scler; 2019 Jul; 25(8):1124-1131. PubMed ID: 29911471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neutropenia with fatal outcome in a multiple sclerosis patient 23 days after alemtuzumab infusion.
    Yiannopoulou KG; Papadimitriou D; Anastasiou AI; Siakantaris M
    Mult Scler Relat Disord; 2018 Jul; 23():15-16. PubMed ID: 29730587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.